← Eichor
Study identifier: NCT05062239 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Post-Operative Atrial Fibrillation After Surgical Aortic Valve Replacement and the Influence of Statins

Condition: Postoperative Atrial Fibrillation  ·  Sponsor: Lars Peter Riber

PhaseNA
Planned participants100
Who can joinAll sexes, 60 Years to 95 Years
Healthy volunteersNo

About this study

Statins have rapid and significant actions that have potentially important (but not yet proven) implications for postoperative atrial fibrillation and cardiac protection in patients undergoing cardiac surgery. The focus of this study is, therefore, on patients having surgical aortic valve replacement (with aortotomy) and the development of postoperative atrial fibrillation (POAF). Our aims are: to investigate the risk of POAF, infection or other complications after SAVR in continuous versus preoperative discontinuous treatment with statins. The study is a single centre randomized controlled trial with continuance treatment with statin vs. discontinuance (7 to 14 days prior surgery until the 30th post-operative day included), on patients undergoing elective solitary SAVR with bioprosthesis with prior usage of statins the last 3 months and of at least 7 days. This randomized studies will address 2 separate hypotheses in patients undergoing open heart operation with solitary aortic valve replacement with a bioprosthetic valve that 1. Discontinuation of HMG-CoA reductase inhibitors 7 to 14 days preoperative until 30 days postoperative of AVR in patients with prior use of HMG-CoA reductase inhibitors is not associated with increased early (\<30 days) risk of POAF. 2. Discontinuation of HMG-CoA reductase inhibitors 7 to 14 days preoperative until 30 days postoperative of AVR in patients with prior use of HMG-CoA reductase inhibitors is not associated with increased early (\<30…

This description comes directly from the study's public registry record.

Talk to the study team

Lytfi Krasniqi, MD  ·  +4542772085  ·  Lytfi.krasniqi@rsyd.dk

Lars Riber, MD  ·  21450354  ·  lars.riber@rsyd.dk

Always discuss trial participation with your own doctor first.

Locations (1)

Odense University HospitalOdense, DenmarkRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05062239